摘要
HBV相关性终末期肝病患者是接受肝移植（LT）治疗的主要群体，而LT术后HBV复发则是LT不得不面对的问题。乙型肝炎免疫球蛋白（HBIG）因其价格昂贵以及长期使用易产生耐药性，现在已很少单独用于临床。目前，LT术后预防HBV复发的标准方案是低剂量HBIG联合核苷酸类似药物（NAs）。近年来，人们开始质疑HBIG在预防HBV复发中的作用，为此一些移植中心相继开展了HBIG—withdrawn和HBIG—free方案，并取得了较好的结果。本文就HBIG在LT术后预防HBV复发应用中的研究现状做一综述，并对HBIG—withdrawn和HBIG—free预防方案的研究前景做一分析。
Patients who suffer from HBV-related endstage liver disease are the majority of liver transplantation （LT） recipients, and hence HBV recurrence post-LT is the key for the treatment success. HBIG was no longer solely used in clinical practice because of high cost and unavoidable drug-resistance. Nowadays, the standard prophylaxis regimen is the combination of low-dose HBIG and nucleoside analogues （NAs）. Recently, the necessity of HBIG usage has been often questioned, and the novel prophylaxis of HBIG-withdrawn and HBIG-free regimen have been carried out in several transplant centers with encoura- ging results. In this review, we summarized the application of HBIG in the prophylaxis of HBV recurrence, and then evaluated the prospect of the prophylaxis of HBIG-withdrawn and HBIG- free regimen.
出处
《中华肝胆外科杂志》
CSCD
北大核心
2017年第7期494-498,共5页
Chinese Journal of Hepatobiliary Surgery
基金
国家自然科学基金新疆联合基金重点支持项目（U1403222）
